{"id":32564,"date":"2022-05-06T14:04:16","date_gmt":"2022-05-06T06:04:16","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=32564"},"modified":"2023-11-13T11:44:13","modified_gmt":"2023-11-13T03:44:13","slug":"elikine-human-pd-l1-elisa-kit%e8%a9%a6%e5%8a%91%e7%9b%92-%e8%b2%a8%e8%99%9fket6036","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=32564","title":{"rendered":"EliKine\u2122 Human PD-L1 ELISA Kit\u8a66\u5291\u76d2 | Abbkine\u8ca8\u865fKTE6036"},"content":{"rendered":"

EliKine\u2122 Human PD-L1 ELISA Kit\u8a66\u5291\u76d2 | \u8ca8\u865fKTE6036<\/a><\/span><\/strong><\/span>\u00a012.5 pg\/mL – 800 pg\/mL, \u00a0\u6700\u4f4e\u9748\u654f\u5ea66.25 pg\/mL<\/u><\/strong><\/span><\/span><\/p>\n

<\/p>\n

\u7522\u54c1<\/strong>\u63cf\u8ff0\uff1a<\/strong>EliKine\u2122 Human PD-L1 ELISA\u8a66\u5291\u76d2\u63a1\u7528\u5169\u9ede\u593e\u5fc3ELISA(Sandwich ELISA)\u5b9a\u91cf\u6a23\u54c1\u4e2d\u7684PD-L1\uff08Programmed Cell Death 1 Ligand 1\uff09\u3002\u5c0dPD-L1\uff08Programmed Cell Death 1 Ligand 1\uff09\u7279\u7570\u7684\u6297\u9ad4\u5df2\u9810\u5148\u5305\u88ab\u5728\u5fae\u5b54\u677f\u4e0a\u3002\u5c07\u6a19\u6e96\u54c1\u548c\u6a23\u54c1\u5438\u53d6\u5230\u5b54\u4e2d\uff0c\u4e26\u4e14\u5b58\u5728\u7684\u4efb\u4f55PD-L1\uff08Programmed Cell Death 1 Ligand 1\uff09\u90fd\u88ab\u56fa\u5b9a\u7684\u6297\u9ad4\u7d50\u5408\u3002\u9664\u53bb\u6240\u6709\u672a\u7d50\u5408\u7684\u7269\u8cea\u5f8c\uff0c\u5c07HRP-\u7db4\u5408PD-L1\uff08Programmed Cell Death 1 Ligand 1\uff09\u6aa2\u6e2c\u6297\u9ad4\u6dfb\u52a0\u5230\u5b54\u4e2d\u3002\u6d17\u6ecc\u4ee5\u9664\u53bb\u4efb\u4f55\u672a\u7d50\u5408\u7684HRP\u8a66\u5291\u5f8c\uff0c\u5c07\u8272\u539f\u6eb6\u6db2\u6dfb\u52a0\u5230\u5b54\u4e2d\uff0c\u4e26\u4e14\u6839\u64da\u5728\u521d\u59cb\u6b65\u9a5f\u4e2d\u7d50\u5408\u7684PD-L1\uff08Programmed Cell Death 1 Ligand 1\uff09\u7684\u91cf\u6210\u6bd4\u4f8b\u5730\u986f\u8272\u3002\u505c\u6b62\u986f\u8272\u4e26\u6e2c\u91cf\u984f\u8272\u7684\u5f37\u5ea6\u3002\u5075\u6e2c\u7bc4\u570d: 12.5 pg\/mL – 800 pg\/mL, \u00a0\u6700\u4f4e\u9748\u654f\u5ea66.25 pg\/mL<\/u><\/strong>\u3002<\/strong>\u53ef\u61c9\u7528\u65bc\u4ee5\u4e0b\u6a23\u54c1\u4f86\u6e90: Cell culture supernatants, Other biological fluids, Plasma, Serum<\/p>\n

\"\"<\/p>\n

\"\u64cd\u4f5c\u624b\u518a\"<\/a><\/strong><\/p>\n

EliKine\u2122 Human PD-L1 ELISA Kit employs a two-site sandwich ELISA to quantitate PD-L1 in samples. An antibody specific for PD-L1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any PD-L1 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for PD-L1 is added to the wells. After washing, proprietary EliKine\u2122 Streptavidin-HRP conjugates is added to the wells. Following a wash to remove any unbound streptavidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of EGF bound in the initial step. The color development is stopped and the intensity of the color is measured.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Product name<\/td>\nEliKine\u2122 Human PD-L1 ELISA Kit<\/a><\/td>\n<\/tr>\n
Reactivity<\/td>\nHuman<\/td>\n<\/tr>\n
Applications<\/td>\nELISA<\/td>\n<\/tr>\n
Applications notes<\/td>\nEliKine\u2122 Human PD-L1 ELISA Kit employs a two-site sandwich ELISA to quantitate PD-L1 in samples. An antibody specific for PD-L1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any PD-L1 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for PD-L1 is added to the wells. After washing, proprietary EliKine\u2122 Streptavidin-HRP conjugates is added to the wells. Following a wash to remove any unbound streptavidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of EGF bound in the initial step. The color development is stopped and the intensity of the color is measured.<\/td>\n<\/tr>\n
Detection method<\/td>\nColorimetric<\/td>\n<\/tr>\n
SampleType<\/td>\nCell culture supernatants, Other biological fluids, Plasma, Serum<\/td>\n<\/tr>\n
Assay type<\/td>\nSandwich ELISA (quantitative)<\/td>\n<\/tr>\n
Assay duration<\/td>\nMultiple steps standard sandwich ELISA assay with a working time of 3-5 hours. It depends on the experience of the operation person.<\/td>\n<\/tr>\n
Alternative<\/td>\nProgrammed Cell Death 1 Ligand 1; PD-L1; PDCD1 Ligand 1; Programmed Death Ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"LINE\u7fa4\u767c(RT-9600)\"<\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n
Kit components<\/td>\n\u2022 Human PD-L1 microplate
\n\u2022 Human PD-L1 standard
\n\u2022 HRP-conjugated Human PD-L1 Detect Antibody
\n\u2022 Sample diluent
\n\u2022 Assay buffer
\n\u2022 HRP substrate (TMB)
\n\u2022 Stop solution
\n\u2022 Wash buffer
\n\u2022 Plate covers.<\/td>\n<\/tr>\n
Features & Benefits<\/td>\nEliKine\u2122 Human PD-L1 ELISA Kit has high sensitivity and excellent specificity for detection of Human PD-L1. No significant cross-reactivity or interference between Human PD-L1 and analogues was observed.<\/td>\n<\/tr>\n
Calibration range<\/td>\n12.5 pg\/mL – 800 pg\/mL<\/td>\n<\/tr>\n
Limit of detection<\/td>\n6.25 pg\/mL<\/td>\n<\/tr>\n
Usage notes<\/td>\n\u2022 Do not mix components from different kit lots or use reagents beyond the kit expiration date.
\n\u2022 Allow all reagents to warm to room temperature for at least 30 minutes before opening.
\n\u2022 Pre-rinse the pipet tip with reagent, use fresh pipet tips for each sample, standard and reagent to avoid contamination.
\n\u2022 Unused wells must be kept desiccated at 4 \u00b0C in the sealed bag provided.
\n\u2022 Mix Thoroughly is very important for the result. It is recommended using low frequency oscillator or slight hand shaking every 10 minutes.
\n\u2022 It is recommended that all samples and standards be assayed in duplicate or triplicate.<\/td>\n<\/tr>\n
Storage instructions<\/td>\nThe unopened kit should be stored at 2 – 8\u00b0C. After opening, please store refer to protocols.<\/td>\n<\/tr>\n
Shipping<\/td>\nGel pack with blue ice.<\/td>\n<\/tr>\n
Precautions<\/td>\nThe product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u7d30\u80de\u56e0\u5b50(Cytokine)\u529f\u80fd<\/strong><\/p>\n

\u7d30\u80de\u56e0\u5b50(Cytokine)\u5177\u6709\u591a\u7a2e\u751f\u7269\u5b78\u529f\u80fd\u3002\u5b83\u662f\u6025\u6027\u671f\u53cd\u61c9(acute phase response)\u7684\u6709\u6548\u8a98\u5c0e\u5291\u3002\u5728B\u7d30\u80de(B-cells)\u6700\u7d42\u5206\u5316\u70baIg\u5206\u6ccc\u7d30\u80de(Ig-secreting cells)\u7684\u6700\u7d42\u5206\u5316\u4e2d\u8d77\u91cd\u8981\u4f5c\u7528\uff0c\u53c3\u8207\u6dcb\u5df4\u7d30\u80de(lymphocyte)\u548c\u55ae\u6838\u7d30\u80de(monocyte)\u7684\u5206\u5316\u3002\u5b83\u8a98\u5c0e\u9aa8\u9ad3\u7624(myeloma)\u548c\u6f3f\u7d30\u80de\u7624(plasmacytoma growth)\u751f\u9577\uff0c\u4e26\u8a98\u5c0e\u795e\u7d93\u7d30\u80de\u5206\u5316(differentiation)\u3002\u4f5c\u7528\u65bcB\u7d30\u80de(B-cells)\uff0cT\u7d30\u80de(T-cells)\uff0c\u809d\u7d30\u80de(hepatocytes)\uff0c\u9020\u8840\u7956\u7d30\u80de(hematopoeitic progenitor cells)\u548cCNS\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u7d30\u80de\u3002\u4e5f\u53ef\u4ee5\u4f5c\u70ba\u808c\u8089\u56e0\u5b50(myokine)\u3002\u5b83\u5728\u808c\u8089\u6536\u7e2e\u5f8c\u6392\u5165\u8840\u6db2\uff0c\u4e26\u8d77\u5230\u589e\u52a0\u8102\u80aa\u5206\u89e3\u548c\u6539\u5584\u80f0\u5cf6\u7d20\u62b5\u6297(insulin resistance)\u7684\u4f5c\u7528\u3002<\/p>\n

\u708e\u6027\u7d30\u80de\u56e0\u5b50<\/strong><\/span><\/p>\n

\u708e\u75c7\u7531\u591a\u7a2e\u53ef\u6eb6\u6027\u56e0\u5b50\u4ecb\u5c0e\uff0c\u5305\u62ec\u4e00\u7d44\u7a31\u70ba\u7d30\u80de\u56e0\u5b50\u7684\u5206\u6ccc\u591a\u80bd\u3002\u708e\u6027\u7d30\u80de\u56e0\u5b50\u53ef\u5206\u70ba\u5169\u985e\uff1a\u53c3\u8207\u6025\u6027\u708e\u75c7\u7684\u7d30\u80de\u56e0\u5b50\u548c\u8ca0\u8cac\u4efb\u7684\u7d30\u80de\u56e0\u5b50\u3002\u708e\u75c7\u662f\u7d44\u7e54\u5c0d\u640d\u50b7\u7684\u53cd\u61c9\uff0c\u5176\u7279\u5fb5\u662f\u5728\u6025\u6027\u671f\u4ee5\u589e\u52a0\u7684\u8840\u6d41\u91cf\u548c\u8840\u7ba1\u901a\u900f\u6027\u4ee5\u53ca\u9ad4\u6db2\uff0c\u767d\u7d30\u80de\u548c\u708e\u6027\u4ecb\u8cea\uff08\u4f8b\u5982\u7d30\u80de\u56e0\u5b50\uff09\u7684\u7a4d\u7d2f\u70ba\u7279\u5fb5\u3002\u5e7e\u7a2e\u7d30\u80de\u56e0\u5b50\u5728\u4ecb\u5c0e\u6025\u6027\u708e\u75c7\u53cd\u61c9\u4e2d\u8d77\u95dc\u9375\u4f5c\u7528\uff0c\u5373IL-1\uff0cTNF-\u03b1\uff0cIL-6\uff0cIL-11\uff0cIL-8\u548c\u5176\u4ed6\u8da8\u5316\u56e0\u5b50\uff0cG-CSF\u548cGM-CSF\u3002<\/p>\n

\u5df2\u77e5\u53ef\u4ecb\u5c0e\u6162\u6027\u708e\u75c7\u904e\u7a0b\u7684\u7d30\u80de\u56e0\u5b50\u53ef\u5206\u70ba\u53c3\u8207\u9ad4\u6db2\u708e\u75c7\u7684\u7d30\u80de\u56e0\u5b50\uff0c\u4f8b\u5982IL-3\uff0cIL-4\uff0cIL-5\uff0cIL-6\uff0cIL-7\uff0cIL-9\uff0cIL-10\uff0cIL- 13\uff0c\u8f49\u5316\u751f\u9577\u56e0\u5b50b\uff08TGF-b\uff09\uff0c\u4ee5\u53ca\u90a3\u4e9b\u6709\u52a9\u65bc\u7d30\u80de\u708e\u75c7\u7684\u56e0\u5b50\uff0c\u4f8b\u5982IL-1\uff0cIL-2\uff0cIL-3\uff0cIL-4\uff0cIL-7\uff0cIL-9\uff0cIL-10\uff0c IL-12\uff0c\u5e72\u64fe\u7d20\uff08IFN\uff09\uff0cIFN-g\u8a98\u5c0e\u56e0\u5b50\uff08IGIF\uff09\uff0cTGF-b\u548cTNF-a\u548c-b\u3002\u708e\u75c7\u7570\u5e38\u662f\u4e00\u5927\u985e\u75be\u75c5\uff0c\u662f\u8a31\u591a\u4eba\u985e\u75be\u75c5\u7684\u57fa\u790e\u3002\u7d30\u80de\u56e0\u5b50\u662f\u5bbf\u4e3b\u5c0d\u611f\u67d3\uff0c\u514d\u75ab\u53cd\u61c9\uff0c\u708e\u75c7\u548c\u5275\u50b7\u53cd\u61c9\u7684\u8abf\u7bc0\u5291\u3002\u4e00\u4e9b\u7d30\u80de\u56e0\u5b50\u8d77\u4f7f\u75be\u75c5\u60e1\u5316\u7684\u4f5c\u7528\uff08\u4fc3\u708e\u7d30\u80de\u56e0\u5b50\uff09\uff0c\u800c\u53e6\u4e00\u4e9b\u7d30\u80de\u56e0\u5b50\u8d77\u6e1b\u8f15\u708e\u75c7\u548c\u4fc3\u9032\u7652\u5408\u7684\u4f5c\u7528\uff08\u6297\u708e\u7d30\u80de\u56e0\u5b50\uff09\u3002<\/p>\n

\u767d\u4ecb\u7d20-1\uff08Interleukin-1, IL-1\uff09\u662f\u6709\u53f2\u4ee5\u4f86\u6700\u65e9\u7684\u7d30\u80de\u56e0\u5b50(cytokines)\u4e4b\u4e00\u3002\u5b83\u7684\u6700\u521d\u767c\u73fe\u662f\u53ef\u80fd\u8a98\u767c\u767c\u71d2(fever)\uff0c\u63a7\u5236\u6dcb\u5df4\u7d30\u80de(lymphocytes)\uff0c\u589e\u52a0\u9aa8\u9ad3\u7d30\u80de\u6578\u91cf(bone marrow cells)\u4e26\u5f15\u8d77\u9aa8\u95dc\u7bc0\u9000\u5316\u7684\u56e0\u7d20\u3002\u6b64\u6642\uff0cIL-1\u4ee5\u5176\u4ed6\u5e7e\u7a2e\u540d\u7a31\u70ba\u4eba\u6240\u77e5\uff0c\u5305\u62ec\u5167\u6e90\u6027\u71b1\u539f(endogenous pyrogen)\uff0c\u6dcb\u5df4\u7d30\u80de\u6d3b\u5316\u56e0\u5b50(lymphocyte activating factor)\uff0c\u9020\u8840\u7d20-1(haemopoetin-1)\u548c\u55ae\u6838\u7d30\u80de\u56e0\u5b50(mononuclear cell factor)\u7b49\u3002\u5927\u7d04\u57281984\u5e74\u81f31985\u5e74\u9593\uff0c\u79d1\u5b78\u5bb6\u5011\u8b49\u5be6IL-1\u5be6\u969b\u4e0a\u7531\u5169\u7a2e\u4e0d\u540c\u7684\u86cb\u767d\u8cea\u7d44\u6210\uff0c\u73fe\u5728\u7a31\u70baIL-1\u03b1\u548cIL-1\u03b2\uff0c\u5b83\u5011\u5c6c\u65bc\u7a31\u70ba\u767d\u7d30\u80de\u4ecb\u7d201\u8d85\u5bb6\u65cf\u7684\u7d30\u80de\u56e0\u5b50\u5bb6\u65cf\u3002 IL-1\u03b2\u7531\u5de8\u566c\u7d30\u80de(macrophages)\uff0c\u55ae\u6838\u7d30\u80de(monocytes)\u548c\u6a39\u7a81\u72c0\u7d30\u80de(dendritic cells)\u7522\u751f\u3002<\/p>\n

IFN-\u03b3\uff08IFN-gamma, \u5e72\u64fe\u7d20-\u03b3\uff09\u662f\u4fc3\u708e(proinflammatory)\u7d30\u80de\u56e0\u5b50(cytokine)\u7684\u539f\u578b(prototype)\uff0c\u7531\u591a\u7a2e\u514d\u75ab\u7d30\u80de(immune cells)\u5728\u708e\u6027(inflammatory)\u689d\u4ef6\u4e0b\u7522\u751f\uff0c\u7279\u5225\u662f\u7531T\u7d30\u80de(T cells)\u548cNK\u7d30\u80de(NK cells)\u7522\u751f\u3002\u5b83\u901a\u904e\u4fc3\u9032Th1\u7d30\u80de\u7684\u767c\u80b2(development)\u548c\u6fc0\u6d3b(activation)\uff0c\u55ae\u6838\u7d30\u80de(monocytes)\u548c\u5de8\u566c\u7d30\u80de(macrophage)\u7684\u5316\u5b78\u5f15\u8a98(chemoattraction)\u548c\u6fc0\u6d3b(activation)\uff0c\u6297\u539f\u5448\u905e\u5206\u5b50(antigen presentation molecules)\u7684\u4e0a\u8abf\u4ee5\u53caB\u7d30\u80de\u4e2d\u7684\u514d\u75ab\u7403\u86cb\u767d\u985e\u5225\u8f49\u63db(immunoglobulin class switching)\uff0c\u5728\u5bbf\u4e3b\u9632\u79a6\u4e2d\u8d77\u95dc\u9375\u4f5c\u7528\u3002\u5b83\u9084\u5177\u6709\u6297\u75c5\u6bd2(antiviral)\uff0c\u6297\u589e\u6b96(antiproliferative)\u548c\u51cb\u4ea1\u4f5c\u7528(apoptotic)\u3002\u53e6\u5916\uff0cIFN-\u03b3\u901a\u904e\u4fc3\u9032\u8abf\u7bc0\u6027T\u7d30\u80de\u7684\u767c\u80b2\u4e26\u6291\u5236Th17\u7d30\u80de\u5206\u5316\u800c\u5145\u7576\u6297\u708e\u4ecb\u8cea\u3002 IFN-\u03b3\u4e8c\u805a\u9ad4\u901a\u904e\u5169\u500bIFN-\u03b3R1\u548c\u5169\u500bIFN-\u03b3R2\u4e9e\u57fa\u7684\u53d7\u9ad4\u8907\u5408\u7269\u767c\u51fa\u4fe1\u865f\u3002<\/p>\n

\u767d\u7d30\u80de\u4ecb\u7d2017 (Interleukin 17, IL17)<\/p>\n

IL-17\u57fa\u56e0\u7de8\u78bc( IL-17 gene)\u7684\u86cb\u767d\u8cea\u662f\u7531\u6d3b\u5316\u7684T\u7d30\u80de(activated T cells)\u6240\u7522\u751f\u7684\u4fc3\u767c\u708e\u7d30\u80de\u6fc0\u7d20\u3002\u6b64\u7d30\u80de\u6fc0\u7d20\u8abf\u7bc0 NF-\u03baB \u548c\u7d72\u88c2\u539f\u6d3b\u5316\u86cb\u767d\u6fc0\u9176(mitogen-activated protein kinases)\u7684\u6d3b\u6027\u3002\u9019\u7a2e\u7d30\u80de\u6fc0\u7d20(cytokine )\u53ef\u4ee5\u523a\u6fc0 IL6 \u548c\u74b0\u6c27\u5408\u9176-2 (cyclooxygenase-2, PTGS2\/COX-2) \u7684\u8868\u9054\uff0c\u4e26\u589e\u5f37\u4e00\u6c27\u5316\u6c2e (nitric oxide, NO) \u7684\u7522\u751f\u3002\u9ad8\u6c34\u5e73\u7684\u9019\u7a2e\u7d30\u80de\u6fc0\u7d20\u8207\u591a\u7a2e\u6162\u6027\u767c\u708e\u6027\u75be\u75c5\u6709\u95dc\uff0c\u5305\u62ec\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(rheumatoid arthritis)\u3001\u725b\u76ae\u766c(psoriasis )\u548c\u591a\u767c\u6027\u786c\u5316\u75c7(multiple sclerosis)\u3002<\/p>\n

\u767d\u8840\u7403\u4ecb\u7d20-8\uff08Interleukin-8, IL8)<\/p>\n

IL-8\u57fa\u56e0\u7de8\u78bc(IL-8 gene)\u7684\u86cb\u767d\u8cea\u662fCXC\u8da8\u5316\u56e0\u5b50\u5bb6\u65cf(CXC chemokine family)\u7684\u6210\u54e1\u3002\u9019\u7a2e\u8da8\u5316\u56e0\u5b50(chemokine )\u662f\u767c\u708e\u53cd\u61c9(inflammatory response)\u7684\u4e3b\u8981\u4ecb\u8cea\u4e4b\u4e00\u3002\u9019\u7a2e\u8da8\u5316\u56e0\u5b50\u7531\u591a\u7a2e\u7d30\u80de\u985e\u578b\u5206\u6ccc\u3002\u5b83\u5177\u6709\u5316\u5b78\u5f15\u8a98\u5291( chemoattractant)\u7684\u4f5c\u7528\uff0c\u4e5f\u662f\u4e00\u7a2e\u6709\u6548\u7684\u8840\u7ba1\u751f\u6210\u56e0\u5b50(angiogenic factor)\u3002 IL-8\u57fa\u56e0\u88ab\u8a8d\u70ba\u5728\u7d30\u652f\u6c23\u7ba1\u708e\uff08\u4e00\u7a2e\u7531\u75c5\u6bd2\u611f\u67d3\u5f15\u8d77\u7684\u5e38\u898b\u547c\u5438\u9053\u75be\u75c5\uff09\u7684\u767c\u75c5\u6a5f\u5236(pathogenesis )\u4e2d\u767c\u63ee\u4f5c\u7528\u3002 IL-8\u57fa\u56e0(IL-8 gene )\u548cCXC\u8da8\u5316\u56e0\u5b50\u57fa\u56e0\u5bb6\u65cf(CXC chemokine gene family)\u7684\u5176\u4ed610\u500b\u6210\u54e1\u5728\u5b9a\u4f4d\u65bc\u67d3\u8272\u9ad44q( chromosome 4q)\u7684\u5340\u57df\u4e2d\u5f62\u6210\u8da8\u5316\u56e0\u5b50\u57fa\u56e0\u7c07(chemokine gene cluster )\u3002<\/p>\n

\"\u6ce8\u610f\u4e8b\u9805\"<\/p>\n